Quick translation
- Ingredient
- Tirzepatide
- Approved brands
- Mounjaro and Zepbound
- Not the same category
- Compounded tirzepatide
Fact check
Approved, compounded or “research”: the words matter
These words describe different products and rules. Mixing them up can hide what is being offered.
STATUS MAP
Name.Status.Source.
Approval
What did FDA approve?
As of September 2026, the approved tirzepatide products are Mounjaro and Zepbound.
FDA approval covers one named product. It covers only the shapes that product comes in, such as pens and vials, and only the health problems listed on its label.
It does not cover every vial or programme that uses the word tirzepatide.
No generic tirzepatide had FDA approval as of September 2026.
Source: FDA drug application recordsCompounding
Can a real compounded medicine lack FDA approval?
Yes. A compounded medicine can be lawfully made for a patient need. It is not FDA-approved.
FDA does not check it for safety, results or quality before it is marketed.
Compounding means a pharmacist or doctor makes a medicine instead of giving out a finished FDA-approved product. Federal law has one set of rules for an ordinary pharmacy that mixes a medicine for a single patient. It has a stricter set, with factory quality rules, for larger outsourcing facilities that make batches.
Source: FDA compounding questions and answersOrdinary pharmacy (“503A”)
This kind of pharmacy mixes a medicine for one named patient. It needs a prescription. The name 503A is only the number of the part of federal law that covers it.
Outsourcing facility (“503B”)
This is a bigger operation that makes batches of germ-free (sterile) medicine, often for clinics and hospitals. It must follow federal factory rules. Neither kind is FDA-approved, so the check for you is the same: the label names the pharmacy, and your state’s licence search lists it.
Shortage status
Why did compounded copies become common?
A national shortage had allowed pharmacies to make copies under shortage rules.
FDA confirmed the tirzepatide injection shortage was resolved on December 19, 2024.
As of September 2026, tirzepatide was not on FDA’s national shortage list.
A local pharmacy being out of stock does not count as a national shortage, so it does not bring back the shortage-time permission for pharmacies to make copies.
Source: FDA shortage decisionImportant: a pharmacy-made copy can still be allowed for a specific patient. The prescriber (the doctor or other professional writing the prescription) has to decide that the change matters for that one patient’s health and write the reason down. Lower price alone is not such a reason under FDA’s stated approach.
Research label
Does the sticker change the product?
No. FDA has told online sellers that a research label does not change the product’s status. That is true when the site is selling it for human use.
Federal law bars selling a prescription medicine without a prescription.
Open the FDA letterDo not let a label answer the wrong question
The useful question is not “What does the sticker say?” It is “Is this Mounjaro or Zepbound from the maker, or a copy mixed for me by a pharmacy that the label names and my state has licensed?”